Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Razidlo, David F ^a   Whitney, Tiffany J ^a   Casper, Michelle E ^a   McGee Lawrence, Meghan E ^a   Stensgard, Bridget A ^a   Li, Xiaodong ^a   Secreto, Frank J ^a   Knutson, Sarah K ^b   Hiebert, Scott W ^b   Westendorf, Jennifer J ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE 3; TRANSCRIPTION FACTOR OSTERIX; HISTONE DEACETYLASE; OSTERIX PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; CELL DIFFERENTIATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; EMBRYO; EPIGENETICS; EXON; FEMALE; FEMUR; GENOTYPE; GROWTH PLATE; HETEROZYGOSITY; LOXP SITE; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; STEM CELL; TRABECULAR BONE; UPREGULATION; ANIMAL; BONE MARROW CELL; CYTOLOGY; DNA MICROARRAY; GENETICS; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; MOUSE MUTANT; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MUS;

ADIPOCYTES; ADIPOGENESIS; ANIMALS; BLOTTING, WESTERN; BONE DENSITY; BONE MARROW CELLS; GENOTYPE; GROWTH PLATE; HISTONE DEACETYLASES; MICE; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOGENESIS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELLS; TRANSCRIPTION FACTORS; X-RAY MICROTOMOGRAPHY;

EID: 77955349977     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011492     Document Type: Article

References (63)

1. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, et al. (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755-764.
2. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, et al. (1997) Cbfal, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89: 765-771.
3. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, et al. (2002) The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108: 17-29.
4. Khosla S, Westendorf JJ, Oursler MJ (2008) Building bone to reverse osteoporosis and repair fractures. J Clin Invest 118: 421-428.
5. Kobayashi H, Gao Y, Ueta C, Yamaguchi A, Komori T (2000) Multilineage differentiation of Cbfa1-deficient calvarial cells in vitro. Biochem Biophys Res Commun 273: 630-636.
6. Enomoto H, Furuichi T, Zanma A, Yamana K, Yoshida C, et al. (2004) Runx2 deficiency in chondrocytes causes adipogenic changes in vitro. J Cell Sci 117: 417-425.
7. Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32-42.
8. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, et al. (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. Embo J 21: 2672-2681.
9. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, et al. (2007) Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 21: 1790-1802.
10. Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, et al. (2007) Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 13: 324-331.
11. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, et al. (2008) Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 30: 61-72.
12. Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S, et al. (2008) Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 118: 3588-3597.
13. Haberland M, Mokalled MH, Montgomery RL, Olson EN (2009) Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev 23: 1625-1630.
14. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, et al. (2004) Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119: 555-566.
15. Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, et al. (2008) Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 28: 1688-1701.
16. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, et al. (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24: 8467-8476.
17. Chang S, Young BD, Li S, Qi X, Richardson JA, et al. (2006) Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126: 321-334.
18. Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, et al. (2001) Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 276: 35826-35835.
19. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, et al. (2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 9: 45-57.
20. Guenther MG, Barak O, Lazar MA (2001) The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 21: 6091-6101.
21. Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA, et al. (2000) A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev 14: 1048-1057.
22. Guenther MG, Yu J, Kao GD, Yen TJ, Lazar MA (2002) Assembly of the SMRT-histone deacetylase 3 repression complex requires the TCP-1 ring complex. Genes Dev 16: 3130-3135.
23. Westendorf JJ (2007) Histone deacetylases in control of skeletogenesis. J Cell Biochem.
24. Schroeder TM, Kahler RA, Li X, Westendorf JJ (2004) Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem 279: 41998-42007.
25. Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, et al. (2002) Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 22: 7982-7992.
26. Jensen ED, Schroeder TM, Bailey J, Gopalakrishnan R, Westendorf JJ (2008) Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. JBone Miner Res 23: 361-372.
27. Makita N, Suzuki M, Asami S, Takahata R, Kohzaki D, et al. (2008) Two of four alternatively spliced isoforms of RUNX2 control osteocalcin gene expression in human osteoblast cells. Gene 413: 8-17.
28. Choo MK, Yeo H, Zayzafoon M (2009) NFATc1 mediates HDAC-dependent transcriptional repression of osteocalcin expression during osteoblast differentiation. Bone.
29. Lamour V, Detry C, Sanchez C, Henrotin Y, Castronovo V, et al. (2007) Runx2- and histone deacetylase 3-mediated repression is relieved in differentiating human osteoblast cells to allow high bone sialoprotein expression. J Biol Chem 282: 36240-36249.
30. Rodda SJ, McMahon AP (2006) Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 133: 3231-3244.
31. Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, et al. (2008) Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. Embo J 27: 1017-1028.
32. Kaback LA, Soung do Y, Naik A, Smith N, Schwarz EM, et al. (2008) Osterix/ Sp7 regulates mesenchymal stem cell mediated endochondral ossification. J Cell Physiol 214: 173-182.
33. Petit MA, Beck TJ, Kontulainen SA (2005) Examining the developing bone: What do we measure and how do we do it? J Musculoskelet Neuronal Interact 5: 213-224.
34. Rosen CJ, Ackert-Bicknell C, Rodriguez JP, Pino AM (2009) Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit Rev Eukaryot Gene Expr 19: 109-124.
35. Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, et al. (1999) Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiprolif-erative effects. J Biol Chem 274: 34940-34947.
36. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97: 10014-10019.
37. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, et al. (2000) Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 60: 6068-6074.
38. Wise LD, Turner KJ, Kerr JS (2007) Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Birth Defects Res B Dev Reprod Toxicol 80: 57-68.
39. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
40. Kawase T, Ohki R, Shibata T, Tsutsumi S, Kamimura N, et al. (2009) PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell 136: 535-550.
41. Zupkovitz G, Tischler J, Posch M, Sadzak I, Ramsauer K, et al. (2006) Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol Cell Biol 26: 7913-7928.
42. Bellosta P, Masramon L, Mansukhani A, Basilico C (2003) p21(WAF1/CIP1) acts as a brake in osteoblast differentiation. J Bone Miner Res 18: 818-826.
43. Murshed M, Schinke T, McKee MD, Karsenty G (2004) Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 165: 625-630.
44. Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, et al. (2002) Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 99: 9445-9449.
45. Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, et al. (2005) Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 102: 3324-3329.
46. Alenghat T, Meyers K, Mullican SE, Leitner K, Adeniji-Adele A, et al. (2008) Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 456: 997-1000.
47. Fajas L, Egler V, Reiter R, Hansen J, Kristiansen K, et al. (2002) The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell 3: 903-910.
48. Ge H, Cha JY, Gopal H, Harp C, Yu X, et al. (2005) Differential regulation and properties of angiopoietin-like proteins 3 and 4. J Lipid Res 46: 1484-1490.
49. Kim KH, Cho YS, Park JM, Yoon SO, Kim KW, et al. (2007) Pro-MMP-2 activation by the PPARgamma agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK. FEBS Lett 581: 3303-3310.
50. Lee HW, Suh JH, Kim AY, Lee YS, Park SY, et al. (2006) Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol Endocrinol 20: 2432-2443.
51. Iwami K, Moriyama T (1993) Effects of short chain fatty acid, sodium butyrate, on osteoblastic cells and osteoclastic cells. Int J Biochem 25: 1631-1635.
52. Schroeder TM, Westendorf JJ (2005) Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 20: 2254-2263.
53. Boer JD, Licht R, Bongers M, Klundert TV, Arends R, et al. (2006) Inhibition of Histone Acetylation as a Tool in Bone Tissue Engineering. Tissue Eng.
54. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, et al. (2000) Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11: 2069-2083.
55. Pratap J, Dhillon R, Li X, Wixted J, Akech J, et al. (2008) The Histone Deacetylase Inhibitor, Vorinostat, Blocks Growth and Associated Osteolysis of Cancer Cells Within Bone, but Reduces Bone Volume in Non-Tumor Bearing Bones in Mice. Journal of Bone and Mineral Research 23 (Suppl 1).
56. Marks PA (2007) Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-1356.
57. Wiech NL, Fisher JF, Helquist P, Wiest O (2009) Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders. Curr Top Med Chem 9: 257-271.
58. McGee-Lawrence ME, Wojda SJ, Barlow LN, Drummer TD, Bunnell K, et al. (2009) Six months of disuse during hibernation does not increase intracortical porosity or decrease cortical bone geometry, strength, or mineralization in black bear (Ursus americanus) femurs. J Biomech 42: 1378-1383.
59. Iwaniec UT, Wronski TJ, Turner RT (2008) Histological Analysis of Bone. In: Nagy LE, ed. Alcohol: Methods and Protocols: Humana Press. pp 325-341.
60. Gallay SH, Miura Y, Commisso CN, Fitzsimmons JS, O'Driscoll SW (1994) Relationship of donor site to chondrogenic potential of periosteum in vitro. J Orthop Res 12: 515-525.
61. Reinholz GG, Fitzsimmons JS, Casper ME, Ruesink TJ, Chung HW, et al. (2009) Rejuvenation of periosteal chondrogenesis using local growth factor injection. Osteoarthritis Cartilage 17: 723-734.
62. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
63. Pfaffl MW (2001) A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 29: e45.